Marijuana Industry Demands Hemp Standards It Never Applied to Itself

Licensed Cannabis Operators Push for Hemp Restrictions

State-licensed marijuana trade groups are petitioning the DEA, FDA, and state legislatures to restrict hemp-derived intoxicating cannabinoids, citing consumer safety and product consistency concerns. According to filings submitted to the DEA's ongoing rescheduling docket and state legislative committees in California, New York, and Illinois, licensed operators argue that hemp products containing delta-8 THC, THCA, and other intoxicating cannabinoids should face the same testing, child-resistant packaging, and potency caps that apply to state-regulated marijuana.

The National Cannabis Roundtable and the U.S. Cannabis Council filed joint comments in July 2026. They're urging the DEA to clarify that any hemp product with intoxicating effects falls under Controlled Substances Act scheduling, not the 2018 Farm Bill's hemp exemption.

Double Standard on Testing and Labeling

Here's the irony: state marijuana programs have never harmonized their own testing protocols, potency disclosure rules, or pesticide limits. A 2025 audit by the Cannabis Regulators Association found that fewer than half of U.S. states with adult-use programs require batch-level cannabinoid profiling beyond total THC and CBD. Terpene disclosure? Optional in 18 states. Pesticide action levels vary by a factor of ten between California and Michigan.

Licensed operators in states with lax testing rules are now asking regulators to impose stricter requirements on hemp competitors than they face themselves. California's Department of Cannabis Control doesn't mandate THCA quantification on labels, yet the California Cannabis Industry Association's 2026 legislative agenda includes a bill requiring hemp products to report THCA separately and cap total THC at 0.3 percent by weight, not just delta-9 THC.

Regulatory Arbitrage Cuts Both Ways

Hemp producers argue that state marijuana programs created the regulatory vacuum by refusing to allow licensed hemp cultivation for cannabinoid extraction. According to the U.S. Hemp Roundtable, 22 states with legal marijuana programs prohibit or heavily restrict licensed hemp growers from selling biomass to extractors. That forces compliant operators into gray-market channels or out-of-state production.

The result is a two-tier system. State-licensed cannabis enjoys monopoly protection in flower and vape markets, while hemp-derived products fill the edibles and beverage gap in states where marijuana edibles face 10 mg per-serving caps or outright bans.

Federal Rescheduling Adds Pressure

The DEA's proposed rescheduling of marijuana to Schedule III under 21 U.S.C. § 812 doesn't resolve the hemp-cannabis divide. The July 2026 Notice of Proposed Rulemaking left the Farm Bill's hemp definition unchanged: cannabis with ≤0.3 percent delta-9 THC by dry weight remains exempt from CSA controls. THCA-rich hemp flower, delta-8 gummies, and HHC vapes stay legal under federal law unless the DEA or FDA issues new guidance.

State-licensed operators want the DEA to adopt a total-THC standard (delta-9 plus THCA) for the hemp exemption, which would effectively ban intoxicating hemp products. Will the DEA address this in the final rule? It hasn't indicated one way or the other. The final rule is expected in early 2027.

What Comes Next

The political variable is state legislatures, not federal agencies. Fourteen states introduced hemp-restriction bills in the first half of 2026. Five passed. The trend favors licensed cannabis lobbies in states with mature marijuana markets and strong tax revenue, while hemp advocates are focusing on states without legal marijuana programs, where hemp-derived products are the only legal intoxicating option.

For full background on the regulatory split between hemp and marijuana, see the CannIntel topic hub on Hemp vs Marijuana Regulation.